Why, IYO, is the Dermatologic and Ophthalmic Drugs Advisory Committee more reluctant to hold an in-person panel than the FDA’s other advisory committees?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”